| Acțiuni restante | 110,427,682 shares |
| Acțiuni Insider | 15.272.836 shares |
| Proprietatea din interior | 13,83 % |
| Total Insiders | 53 |
Scorul de sentimente din interior
Insider Sentiment Score găsește companiile cumpărate de persoane din interior.
Este rezultatul unui model cantitativ sofisticat, multifactorial, care identifică companiile cu cele mai înalte niveluri de acumulare de persoane interne. Modelul de scoring folosește o combinație a numărului net de persoane din interior care cumpără în ultimele 90 de zile, totalul acțiunilor cumpărate ca procent din flota și totalul acțiunilor deținute de insider. Numărul variază de la 0 la 100, numerele mai mari indicând un nivel mai ridicat de acumulare pentru semenii săi, iar 50 fiind media.
Frecvența actualizării: zilnic
Scorul de sentiment al ofițerului
Scorul de sentiment al ofițerilor găsește companii cumpărate de ofițerii corporativi.
Prin definiție, Ofițerii Corporativi sunt Corporate Insiders, dar spre deosebire de unii dintre ceilalți Insiders (10% Acționari și Membri ai Consiliului de Administrație), Ofițerii lucrează zilnic pentru companie și își folosesc banii atunci când tranzacționează . (10% acționari și membri ai consiliului de administrație sunt adesea administratori de fonduri care gestionează banii altor persoane.) Ca atare, tranzacțiile privilegiate efectuate de către ofițeri sunt mult mai semnificative și ar trebui tratate în mod corespunzător.
La fel ca Scorul Sentimentului Insider, Scorul Sentimentului Ofițerului este rezultatul unui model cantitativ sofisticat, multifactorial, care identifică companiile cu cele mai înalte niveluri de acumulare de ofițeri.
Frecvența actualizării: zilnic
Vedeți Top Picks Insiders, care oferă o listă a companiilor cu cel mai mare sentiment din interior.
Valori cheie ale insiderului
Acest card arată modul în care compania se clasifică de-a lungul diferitelor valori interne. Clasamentul percentilei arată cum se compară această companie cu alte companii de pe piețele din SUA. Clasamentele mai înalte indică situații mai bune.
De exemplu, este în general acceptat că cumpărarea din interior este un indicator pozitiv, astfel încât companiile cu mai multe achiziții din interior s-ar clasa mai sus decât companiile cu mai puține achiziții din interior (sau chiar vânzări din interior).
Numărul net de persoane din interior care cumpără (clasament)
404 out of 10948
Numărul net de persoane din interior care cumpără este numărul total de persoane din interior care cumpără minus numărul total de persoane din interior care au vândut în ultimele 90 de zile. Rangul percentilei este afișat aici (interval de la 0 la 100%).
Procent din flota cumpărată de persoane din interior (clasament)
109 out of 10786
Procent of Float Bought by Insiders este numărul total de acțiuni cumpărate de insiders minus numărul total de acțiuni vândute de insiders în ultimele 90 de zile, împărțit la flota totală și înmulțit cu 100.
Graficul privind tranzacțiile privilegiate
Viridian Therapeutics, Inc. tranzacții privilegiate sunt prezentate în graficul următor. Insiders sunt ofițeri, directori sau investitori importanți într-o companie. În general, este în general ilegal ca persoanele din interior să facă tranzacții în companiile lor pe baza unor informații materiale, nepublice. Acest lucru nu înseamnă că este ilegal pentru ei să facă tranzacții în propriile companii. Cu toate acestea, ei trebuie să raporteze toate tranzacțiile către SEC printr-un Formular 4.
Lista de persoane din interior și valori de profitabilitate
Acest tabel prezintă lista persoanelor din interior cunoscute și este generată automat din dosarele dezvăluite SEC. Pe lângă nume, cel mai recent titlu și desemnarea directorului, a ofițerului sau a proprietarului în proporție de 10%, oferim cele mai recente dețineri divulgate. În plus, atunci când este posibil, oferim performanța comercială istorică pentru persoane din interior. Performanța comercială istorică este o medie ponderată a performanței tranzacțiilor reale de cumpărare pe piață deschisă efectuate de către insider. Pentru mai multe informații despre cum se calculează, urmăriți acest webinar YouTube.
See our leaderboard of most profitable insider traders.
| Insider | Profit mediu (%) | Acțiuni Deținut |
Despică Ajustat |
|---|---|---|---|
|
Atlas Venture Fund VII L P
10% Owner -
|
6.285.160 | 419.011 | |
| Beetham Thomas W. Chief Operating Officer - [O] | 13.361 | 13.361 | |
| Bruce Booth Director - [D] | 1.351.090 | 90.073 | |
| Christopher Bowden | 24.000 | ||
|
Cohen Steven A/sac Capital Mgmt Lp
10% Owner -
|
426.162 | 426.162 | |
| Thomas Ciulla Chief Medical Officer - [O] | 762 | 762 | |
| John W Creecy Director - [D] | 5.413.126 | 360.875 | |
| Diana Escolar | 270.000 | ||
|
Fhmlsp, L.l.c.
10% Owner -
|
1.505.200 | 1.505.200 | |
|
Fhmlsp, L.p.
10% Owner -
|
1.505.200 | 1.505.200 | |
|
Fairmount Funds Management LLC
Director, 10% Owner -
[D]
|
5.090.928 | 5.090.928 | |
| Fairmount Healthcare Fund GP LLC Director - [D] | 938.233 | 1.845.813 | |
| Fairmount Healthcare Fund II GP LLC Director - [D] | 938.233 | 5.090.928 | |
| Fairmount Healthcare Fund II L.P. Director - [D] | 938.233 | 5.090.928 | |
| Fairmount Healthcare Fund L.P. Director - [D] | 938.233 | 1.845.813 | |
|
Frazier Life Sciences Public Fund, L.P.
10% Owner -
|
1.505.200 | 1.505.200 | |
| David A Gonyer Director - [D] | 1.899 | 1.899 |
| Insider | Profit mediu (%) | Acțiuni Deținut |
Despică Ajustat |
|---|---|---|---|
| Seth Harmon Chief Financial Officer - [O] | 7.850 | 7.850 | |
| Peter Evan Harwin | 24.000 | ||
| Hatfield Jeffrey S. | 24.000 | ||
| Hughes Thomas E. Director - [D] | 12.827 | 855 | |
| Kristian Humer | 90.000 | ||
| Robert Brian Johnson | 0 | ||
| Kevin Koch | 24.000 | ||
| Barrett Katz Chief Medical Officer - [O] | 0 | 0 | |
| Tomas Kiselak | 24.000 | ||
|
Peter Kolchinsky
10% Owner -
|
410.686 | 410.686 | |
|
Alpha, Lllp Lebow
10% Owner -
|
4.465.258 | 4.465.258 | |
|
Bennett S Lebow
Director, 10% Owner -
[D]
|
280.600 | 18.707 | |
| Kyle Lefkoff Director - [D] | 463.473 | 30.898 | |
| Leverone Jason A. CFO, Treasurer & Secretary - [O] | 48.829 | 3.255 | |
| Adam Scott Levy Chief Business Officer - [O] | 10.540 | 703 | |
|
Logos Global Master Fund LP
10% Owner -
|
550.000 | 550.000 | |
| Mahoney Stephen F. President and CEO, Director - [D] [O] | 33.349 | 33.349 | |
| William Stuart Marshall President & CEO, Director - [D] [O] | 270.646 | 18.043 |
| Insider | Profit mediu (%) | Acțiuni Deținut |
Despică Ajustat |
|---|---|---|---|
| Lara Meisner Chief Legal Officer - [O] | 29.971 | 29.971 | |
| Arlene Morris | 24.000 | ||
| Scott Dunseth Myers Chief Executive Officer, Director - [D] [O] | 259.500 | 259.500 | |
|
Point72 Asset Management, L.P.
10% Owner -
|
426.162 | 426.162 | |
|
Point72 Capital Advisors, Inc.
10% Owner -
|
426.162 | 426.162 | |
|
Ra Capital Management, Llc
10% Owner -
|
410.686 | 410.686 | |
|
RA Capital Healthcare Fund LP
10% Owner -
|
410.686 | 410.686 | |
| Paul D Rubin | 87.000 | ||
| Rauch Lee M. | 900.000 | ||
|
Remeditex Ventures LLC
10% Owner -
|
5.413.126 | 360.875 | |
| Samuel D Riccitelli President & CEO, Director - [D] [O] | 571.370 | 571.370 | |
| Tamara A Seymour CFO, Secretary, Treasurer - [O] | 106.447 | 106.447 | |
| Douglas A Schuling Director - [D] | 10.500 | 10.500 | |
|
Shah Rajeev M.
10% Owner -
|
410.686 | 410.686 | |
| Robin L Smith Director - [D] | 1.900 | 1.900 | |
| Joseph L Turner | 24.000 | ||
| Jennifer Tousignant Chief Legal Officer - [O] | 3.494 | 3.494 | |
| Jonathan Violin Chief Executive Officer, Director - [D] [O] | 480.905 | 480.905 |
Report errors via our new Insider Auditing Tool
Înregistrări ale achizițiilor interne - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în VRDN / Viridian Therapeutics, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție și rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate reprezintă acțiunile ajustate în funcție de divizarea.
Înregistrări ale vânzărilor din interior - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în VRDN / Viridian Therapeutics, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție și rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate reprezintă acțiunile ajustate în funcție de divizarea.
Istoricul tranzactiilor
Faceți clic pe pictograma link pentru a vedea istoricul complet al tranzacțiilor. Tranzacțiile raportate ca parte a unui plan de tranzacționare automată 10b5-1 vor avea un X în coloana marcată 10b-5.
| Fişier Data |
Comerț Data |
Formă | Insider | Ticker | Titlul de securitate | Cod | Direct | Exercițiu Preț |
Unitate Preț |
Unități Schimbat |
Valoare Schimbat (1K) |
Rămas Opțiuni |
Rămas Acțiuni |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | 2026-05-11 | 4 | Fairmount Funds Management LLC By Fairmount Healthcare Fund II L.P. | VRDN | Common Stock | I | 17,0000 | 1.176.470 | 20.000 | 5.090.928 | ||||
| 2026-03-09 | 2026-03-03 | 4/A | Harmon Seth | VRDN | Common Stock | D | 30,1900 | -2.031 | -61 | 7.850 | ||||
| 2026-03-09 | 2026-03-03 | 4/A | Beetham Thomas W. | VRDN | Common Stock | D | 30,1900 | -3.048 | -92 | 13.361 | ||||
| 2026-03-09 | 2026-03-03 | 4/A | Mahoney Stephen F. | VRDN | Common Stock | D | 30,1900 | -7.408 | -224 | 33.349 | ||||
| 2026-03-09 | 2026-03-03 | 4/A | Tousignant Jennifer | VRDN | Common Stock | D | 30,1900 | -1.675 | -51 | 3.494 | ||||
| 2026-03-04 | 2026-03-03 | 4 | Tousignant Jennifer | VRDN | Common Stock | D | 29,3200 | -1.724 | -51 | 3.445 | ||||
| 2026-03-04 | 2026-03-03 | 4 | Tousignant Jennifer | VRDN | Common Stock | D | 5.169 | 5.169 | ||||||
| 2026-03-04 | 2026-03-03 | 4 | Harmon Seth | VRDN | Common Stock | D | 29,3200 | -2.091 | -61 | 7.790 | ||||
| 2026-03-04 | 2026-03-03 | 4 | Harmon Seth | VRDN | Common Stock | D | 6.267 | 9.881 | ||||||
| 2026-03-04 | 2026-03-03 | 4 | Beetham Thomas W. | VRDN | Common Stock | D | 29,3200 | -3.138 | -92 | 13.271 | ||||
| 2026-03-04 | 2026-03-03 | 4 | Beetham Thomas W. | VRDN | Common Stock | D | 9.409 | 16.409 | ||||||
| 2026-03-04 | 2026-03-03 | 4 | Mahoney Stephen F. | VRDN | Common Stock | D | 29,3200 | -7.627 | -224 | 33.130 | ||||
| 2026-03-04 | 2026-03-03 | 4 | Mahoney Stephen F. | VRDN | Common Stock | D | 18.357 | 40.757 | ||||||
| 2026-01-02 | 2025-12-31 | 4 | Tousignant Jennifer | VRDN | Common Stock | D | 31,1600 | -2.272 | -71 | 0 | ||||
| 2025-10-27 | 2025-10-23 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | VRDN | Common Stock | I | 22,0000 | 454.545 | 10.000 | 3.914.458 | ||||
| 2025-06-11 | 2025-06-10 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | VRDN | Common Stock | I | 12,3100 | 12.500 | 154 | 3.459.913 | ||||
| 2025-06-11 | 2025-06-09 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | VRDN | Common Stock | I | 7,8000 | 1.600 | 12 | 3.447.413 | ||||
| 2024-09-30 | 2024-09-27 | 4 | Beetham Thomas W. | VRDN | Common Stock | D | 23,4100 | 5.000 | 117 | 6.000 | ||||
| 2024-09-30 | 2024-09-27 | 4 | Mahoney Stephen F. | VRDN | Common Stock | D | 23,3300 | 21.400 | 499 | 21.400 | ||||
| 2024-09-17 | 2024-09-13 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | VRDN | Common Stock | I | 18,7500 | 1.600.000 | 30.000 | 3.445.813 | ||||
| 2024-04-01 | 2024-03-28 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | VRDN | Common Stock | I | 5.859 | 1.845.813 | ||||||
| 2024-04-01 | 2024-03-28 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund LP | VRDN | Common Stock | I | -5.859 | 0 | ||||||
| 2024-01-24 | 2024-01-22 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | VRDN | Common Stock | I | 21,0000 | 476.190 | 10.000 | 1.839.954 | ||||
| 2024-01-12 | 3 | Ciulla Thomas | VRDN | Common Stock | D | 762 | ||||||||
| 2023-06-20 | 2023-06-16 | 4 | Meisner Lara | VRDN | Common Stock | D | 28,3500 | -27 | -1 | 29.971 | ||||
| 2023-06-20 | 2023-06-16 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 27 | 1 | 29.998 | ||||
| 2023-06-20 | 2023-06-15 | 4 | Meisner Lara | VRDN | Common Stock | D | 28,0200 | -2.269 | -64 | 29.971 | ||||
| 2023-06-20 | 2023-06-15 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 2.269 | 52 | 32.240 | ||||
| 2023-06-06 | 2023-06-06 | 4 | Meisner Lara | VRDN | Common Stock | D | 25,0200 | -5.126 | -128 | 29.971 | ||||
| 2023-06-06 | 2023-06-06 | 4 | Meisner Lara | VRDN | Common Stock | D | 18,5100 | 5.126 | 95 | 35.097 | ||||
| 2023-06-06 | 2023-06-05 | 4 | Meisner Lara | VRDN | Common Stock | D | 25,0300 | -499 | -12 | 29.971 | ||||
| 2023-06-06 | 2023-06-05 | 4 | Meisner Lara | VRDN | Common Stock | D | 18,5100 | 499 | 9 | 30.470 | ||||
| 2023-06-06 | 2023-06-02 | 4 | Meisner Lara | VRDN | Common Stock | D | 24,2100 | -1.875 | -45 | 29.971 | ||||
| 2023-06-06 | 2023-06-02 | 4 | Meisner Lara | VRDN | Common Stock | D | 14,0000 | 1.875 | 26 | 31.846 | ||||
| 2023-04-12 | 2023-04-12 | 4 | Myers Scott Dunseth | VRDN | Common Stock | D | 25,3697 | 4.000 | 101 | 259.500 | ||||
| 2023-03-13 | 2023-03-13 | 4 | Myers Scott Dunseth | VRDN | Common Stock | D | 29,1499 | 5.500 | 160 | 255.500 | ||||
| 2023-03-10 | 2023-03-09 | 4 | Meisner Lara | VRDN | Common Stock | D | 29,0700 | -29.971 | -871 | 0 | ||||
| 2023-02-07 | 2023-02-06 | 4 | Myers Scott Dunseth | VRDN | Common Stock | D | 250.000 | 250.000 | ||||||
| 2023-02-07 | 2023-02-02 | 4/A | Violin Jonathan | VRDN | Common Stock | D | 36,8000 | -50.000 | -1.840 | 480.905 | ||||
| 2023-02-07 | 2023-02-02 | 4/A | Violin Jonathan | VRDN | Common Stock | D | 0,1500 | 50.000 | 8 | 530.905 | ||||
| 2023-02-03 | 2023-02-02 | 4 | Violin Jonathan | VRDN | Common Stock | D | 36,8000 | -50.000 | -1.840 | 430.905 | ||||
| 2023-01-25 | 2023-01-23 | 4 | Meisner Lara | VRDN | Common Stock | D | 35,6600 | -6.843 | -244 | 0 | ||||
| 2023-01-25 | 2023-01-23 | 4 | Meisner Lara | VRDN | Common Stock | D | 14,0000 | 1.872 | 26 | 6.843 | ||||
| 2023-01-25 | 2023-01-23 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 4.971 | 114 | 4.971 | ||||
| 2023-01-18 | 2023-01-17 | 4 | Katz Barrett | VRDN | Common Stock | D | 37,2100 | -24.853 | -925 | 0 | ||||
| 2023-01-18 | 2023-01-17 | 4 | Katz Barrett | VRDN | Common Stock | D | 23,0300 | 24.853 | 572 | 24.853 | ||||
| 2023-01-18 | 2023-01-13 | 4 | Katz Barrett | VRDN | Common Stock | D | 37,0100 | -4.147 | -153 | 0 | ||||
| 2023-01-18 | 2023-01-13 | 4 | Katz Barrett | VRDN | Common Stock | D | 23,0300 | 4.147 | 96 | 4.147 | ||||
| 2023-01-11 | 2023-01-10 | 4 | Katz Barrett | VRDN | Common Stock | D | 35,3000 | -47.377 | -1.672 | 0 | ||||
| 2023-01-11 | 2023-01-10 | 4 | Katz Barrett | VRDN | Common Stock | D | 23,0300 | 47.377 | 1.091 | 47.377 | ||||
| 2023-01-11 | 2023-01-09 | 4 | Katz Barrett | VRDN | Common Stock | D | 33,0400 | -12.623 | -417 | 0 | ||||
| 2023-01-11 | 2023-01-09 | 4 | Katz Barrett | VRDN | Common Stock | D | 23,0300 | 12.623 | 291 | 12.623 | ||||
| 2022-12-22 | 2022-12-21 | 4 | Meisner Lara | VRDN | Common Stock | D | 29,1900 | -16.326 | -477 | 0 | ||||
| 2022-12-22 | 2022-12-21 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 16.326 | 376 | 16.326 | ||||
| 2022-12-22 | 2022-12-20 | 4 | Meisner Lara | VRDN | Common Stock | D | 28,0700 | -600 | -17 | 0 | ||||
| 2022-12-22 | 2022-12-20 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 600 | 14 | 600 | ||||
| 2022-12-19 | 2022-12-16 | 4 | Meisner Lara | VRDN | Common Stock | D | 28,4400 | -1.297 | -37 | 0 | ||||
| 2022-12-19 | 2022-12-16 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 1.297 | 30 | 1.297 | ||||
| 2022-12-19 | 2022-12-15 | 4 | Meisner Lara | VRDN | Common Stock | D | 28,0800 | -300 | -8 | 0 | ||||
| 2022-12-19 | 2022-12-15 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 300 | 7 | 300 | ||||
| 2022-12-14 | 2022-12-14 | 4 | Meisner Lara | VRDN | Common Stock | D | 28,1200 | -15.656 | -440 | 0 | ||||
| 2022-12-14 | 2022-12-14 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 15.656 | 361 | 15.656 | ||||
| 2022-12-14 | 2022-12-12 | 4 | Meisner Lara | VRDN | Common Stock | D | 28,0500 | -600 | -17 | 0 | ||||
| 2022-12-14 | 2022-12-12 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 600 | 14 | 600 | ||||
| 2022-11-16 | 2022-11-15 | 4 | Meisner Lara | VRDN | Common Stock | D | 22,0500 | -8.125 | -179 | 0 | ||||
| 2022-11-16 | 2022-11-15 | 4 | Meisner Lara | VRDN | Common Stock | D | 14,0000 | 8.125 | 114 | 8.125 | ||||
| 2022-08-19 | 2022-08-17 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | VRDN | Common Stock | I | 23,5000 | 425.531 | 10.000 | 1.363.764 | ||||
| 2022-06-02 | 2022-06-01 | 4 | Violin Jonathan | VRDN | Common Stock | D | 12,2000 | -30.000 | -366 | 480.905 | ||||
| 2022-05-04 | 2022-05-02 | 4 | Violin Jonathan | VRDN | Common Stock | D | 13,0400 | -30.000 | -391 | 510.905 | ||||
| 2022-04-05 | 2022-04-04 | 4 | Violin Jonathan | VRDN | Common Stock | D | 18,9300 | -3.600 | -68 | 540.905 | ||||
| 2022-04-05 | 2022-04-01 | 4 | Violin Jonathan | VRDN | Common Stock | D | 18,9200 | -26.400 | -499 | 544.505 | ||||
| 2022-03-03 | 2022-03-02 | 4 | Violin Jonathan | VRDN | Common Stock | D | 17,3600 | -11.106 | -193 | 570.905 | ||||
| 2022-03-03 | 2022-03-01 | 4 | Violin Jonathan | VRDN | Common Stock | D | 17,8200 | -18.894 | -337 | 582.011 | ||||
| 2022-02-03 | 2022-02-02 | 4 | Humer Kristian | VRDN | Stock Option (Right to Buy) | D | 18,51 | 90.000 | 90.000 | |||||
| 2022-02-03 | 2022-02-02 | 4 | Katz Barrett | VRDN | Stock Option (Right to Buy) | D | 18,51 | 110.000 | 110.000 | |||||
| 2022-02-03 | 2022-02-02 | 4 | Meisner Lara | VRDN | Stock Option (Right to Buy) | D | 18,51 | 90.000 | 90.000 | |||||
| 2022-02-03 | 2022-02-03 | 4 | Violin Jonathan | VRDN | Common Stock | D | 19,1600 | -909 | -17 | 600.905 | ||||
| 2022-02-03 | 2022-02-02 | 4 | Violin Jonathan | VRDN | Stock Option (Right to Buy) | D | 18,51 | 280.000 | 280.000 | |||||
| 2022-02-03 | 2022-02-02 | 4 | Violin Jonathan | VRDN | Common Stock | D | 18,4700 | -12.340 | -228 | 601.814 | ||||
| 2022-02-03 | 2022-02-01 | 4 | Violin Jonathan | VRDN | Common Stock | D | 19,5500 | -16.751 | -327 | 614.154 | ||||
| 2022-01-03 | 2021-12-31 | 4 | Humer Kristian | VRDN | Stock Option (Right to Buy) | D | 19,77 | 121.371 | 121.371 | |||||
| 2021-12-10 | 2021-12-08 | 4 | Violin Jonathan | VRDN | Series A Non-Voting Convertible Preferred Stock | D | -9.413 | 0 | ||||||
| 2021-12-10 | 2021-12-08 | 4 | Violin Jonathan | VRDN | Common Stock | D | 627.564 | 630.905 | ||||||
| 2021-09-28 | 2021-09-23 | 4 | Frazier Life Sciences Public Fund, L.P. | VRDN | Common Stock | D | 11,0000 | 200.000 | 2.200 | 1.505.200 | ||||
| 2021-09-23 | 2021-09-21 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | VRDN | Common Stock | I | 11,0000 | 909.000 | 9.999 | 938.233 | ||||
| 2021-08-26 | 3 | FHMLSP, L.P. | VRDN | Common Stock | D | 1.305.200 | ||||||||
| 2021-07-27 | 2021-07-26 | 4 | Humer Kristian | VRDN | Stock Option (Right to Buy) | D | 17,09 | 360.000 | 360.000 | |||||
| 2021-07-15 | 2021-07-14 | 4 | Moses Jennifer K. | VRDN | Stock Option (Right to Buy) | D | 17,88 | 25.000 | 25.000 | |||||
| 2021-06-16 | 2021-06-03 | 4 | Kiselak Tomas | VRDN | Stock Option (Right to Buy) | D | 16,60 | 12.500 | 12.500 | |||||
| 2021-06-16 | 2021-06-03 | 4 | Harwin Peter Evan | VRDN | Stock Option (Right to Buy) | D | 16,60 | 12.500 | 12.500 | |||||
| 2021-06-16 | 2021-06-03 | 4 | Morris Arlene | VRDN | Stock Option (Right to Buy) | D | 16,60 | 12.500 | 12.500 | |||||
| 2021-02-08 | 2021-02-04 | 4 | TURNER JOSEPH L | VRDN | Director Stock Option (Right to Buy) | D | 20,50 | 25.000 | 25.000 | |||||
| 2021-02-08 | 2021-02-04 | 4 | Harwin Peter Evan | VRDN | Director Stock Option (Right to Buy) | D | 20,50 | 25.000 | 25.000 | |||||
| 2021-02-08 | 2021-02-04 | 4 | Hatfield Jeffrey S. | VRDN | Director Stock Option (Right to Buy) | D | 20,50 | 25.000 | 25.000 | |||||
| 2021-02-08 | 2021-02-04 | 4 | Kiselak Tomas | VRDN | Director Stock Option (Right to Buy) | D | 20,50 | 25.000 | 25.000 | |||||
| 2021-02-08 | 2021-02-04 | 4 | Morris Arlene | VRDN | Director Stock Option (Right to Buy) | D | 20,50 | 25.000 | 25.000 | |||||
| 2021-01-21 | 2021-01-18 | 4 | Katz Barrett | VRDN | Employee Stock Option (right to buy) | D | 23,03 | 356.000 | 356.000 | |||||
| 2021-01-20 | 2021-01-18 | 4 | Leverone Jason A. | VRDN | Employee Stock Option (right to buy) | D | 23,03 | 311.785 | 311.785 | |||||
| 2021-01-20 | 2021-01-18 | 4 | Violin Jonathan | VRDN | Employee Stock Option (right to buy) | D | 23,03 | 800.075 | 800.075 | |||||
| 2021-01-19 | 2021-01-18 | 4 | Rauch Lee M. | MGEN | Employee Stock Option (right to buy) | D | 23,03 | 15.000 | 15.000 | |||||
| 2020-12-17 | 3 | Shah Rajeev M. | MGEN | Common Stock | I | 410.686 | ||||||||
| 2020-11-20 | 3 | COHEN STEVEN A/SAC CAPITAL MGMT LP See footnotes | MGEN | Common Stock | I | 426.162 | ||||||||
| 2020-11-16 | 2020-11-13 | 4 | Logos Global Master Fund LP | MGEN | Common Stock | D | 14,8389 | 126.667 | 1.880 | 550.000 | ||||
| 2020-11-16 | 2020-11-09 | 4 | Logos Global Master Fund LP | MGEN | Common Stock | D | 1,1641 | 100.000 | 116 | 6.350.000 | ||||
| 2020-11-16 | 2020-11-09 | 4 | Logos Global Master Fund LP | MGEN | Common Stock | D | 1,0979 | 250.000 | 274 | 6.250.000 | ||||
| 2020-11-16 | 3 | Logos Global Master Fund LP | MGEN | Common Stock | D | 6.000.000 | ||||||||
| 2020-10-30 | 2020-10-27 | 4 | Violin Jonathan | MGEN | Series A Non-Voting Convertible Preferred Stock | D | 9.413 | 9.413 | ||||||
| 2020-10-30 | 2020-10-27 | 4 | Violin Jonathan | MGEN | Employee Stock Option (Right to Buy) | D | 0,01 | 4.338.079 | 4.338.079 | |||||
| 2020-10-30 | 2020-10-27 | 4 | Violin Jonathan | MGEN | Common Stock | D | 50.124 | 50.124 | ||||||
| 2020-10-30 | 3 | Violin Jonathan | MGEN | Common Stock | D | 50.124 | ||||||||
| 2020-10-30 | 2020-10-30 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | MGEN | Series A Non-Voting Convertible Preferred Stock | I | 465,9600 | 28.843 | 13.440 | 111.192 | ||||
| 2020-10-30 | 2020-10-30 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund LP | MGEN | Series A Non-Voting Convertible Preferred Stock | I | 465,9600 | 5.494 | 2.560 | 21.999 | ||||
| 2020-10-30 | 3 | Fairmount Healthcare Fund II L.P. By funds | MGEN | Common Stock | I | 526.393 | ||||||||
| 2020-10-29 | 2020-10-27 | 4 | Kiselak Tomas | MGEN | Director Stock Option (Right to Buy) | D | 0,52 | 24.000 | 24.000 | |||||
| 2020-10-29 | 2020-10-27 | 4 | Harwin Peter Evan | MGEN | Director Stock Option (Right to Buy) | D | 0,52 | 24.000 | 24.000 | |||||
| 2020-10-29 | 2020-10-27 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | MGEN | Series A Non-Voting Convertible Preferred Stock | I | 82.349 | 82.349 | ||||||
| 2020-10-29 | 2020-10-27 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund LP | MGEN | Series A Non-Voting Convertible Preferred Stock | I | 16.505 | 16.505 | ||||||
| 2020-10-29 | 2020-10-27 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | MGEN | Common Stock | I | 438.502 | 438.502 | ||||||
| 2020-10-29 | 2020-10-27 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund LP | MGEN | Common Stock | I | 87.891 | 87.891 | ||||||
| 2020-09-17 | 2020-09-13 | 4/A | Rauch Lee M. | MGEN | Stock Option (right to buy) | D | 0,91 | 900.000 | 900.000 | |||||
| 2020-09-15 | 2020-09-14 | 4 | Rauch Lee M. | MGEN | Stock Option (right to buy) | D | 0,91 | 900.000 | 900.000 | |||||
| 2020-05-22 | 2020-05-21 | 4 | Hatfield Jeffrey S. | MGEN | Stock Option (right to buy) | D | 0,63 | 24.000 | 24.000 | |||||
| 2020-05-22 | 2020-05-21 | 4 | TURNER JOSEPH L | MGEN | Stock Option (right to buy) | D | 0,63 | 24.000 | 24.000 | |||||
| 2020-05-22 | 2020-05-21 | 4 | Hughes Thomas E. | MGEN | Stock Option (right to buy) | D | 0,63 | 24.000 | 24.000 | |||||
| 2020-05-22 | 2020-05-21 | 4 | KOCH KEVIN | MGEN | Stock Option (right to buy) | D | 0,63 | 24.000 | 24.000 | |||||
| 2020-05-22 | 2020-05-21 | 4 | Morris Arlene | MGEN | Stock Option (right to buy) | D | 0,63 | 24.000 | 24.000 | |||||
| 2020-05-22 | 2020-05-21 | 4 | Bowden Christopher | MGEN | Stock Option (right to buy) | D | 0,63 | 24.000 | 24.000 | |||||
| 2020-03-17 | 2020-03-13 | 4 | Leverone Jason A. | MGEN | Stock Option (right to buy) | D | 0,57 | -11.249 | 0 | |||||
| 2020-03-17 | 2020-03-13 | 4 | Leverone Jason A. | MGEN | Common Stock | D | 0,5700 | 11.249 | 6 | 48.829 | ||||
| 2020-02-14 | 2020-02-12 | 4 | Marshall William Stuart | MGEN | Stock Option (right to buy) | D | 0,80 | 464.000 | 464.000 | |||||
| 2020-02-14 | 2020-02-12 | 4 | Leverone Jason A. | MGEN | Stock Option (right to buy) | D | 0,80 | 185.000 | 185.000 | |||||
| 2020-02-14 | 2020-02-12 | 4 | Escolar Diana | MGEN | Stock Option (right to buy) | D | 0,80 | 270.000 | 270.000 | |||||
| 2020-02-13 | 2019-08-21 | 5 | Marshall William Stuart | MGEN | Common Stock | D | 1,1390 | 1.250 | 1 | 270.646 | ||||
| 2020-02-13 | 2019-02-21 | 5 | Marshall William Stuart | MGEN | Common Stock | D | 2,4565 | 1.250 | 3 | 269.396 | ||||
| 2019-08-23 | 2019-08-23 | 4 | Leverone Jason A. | MGEN | Stock Option (right to buy) | D | 0,57 | -3.093 | 0 | |||||
| 2019-08-23 | 2019-08-23 | 4 | Leverone Jason A. | MGEN | Common Stock | D | 0,5700 | 3.093 | 2 | 36.330 | ||||
| 2019-06-21 | 2019-06-19 | 4 | Bowden Christopher | MGEN | Stock Option (right to buy) | D | 2,36 | 12.000 | 12.000 | |||||
| 2019-06-21 | 2019-06-19 | 4 | Hatfield Jeffrey S. | MGEN | Stock Option (right to buy) | D | 2,36 | 12.000 | 12.000 | |||||
| 2019-06-21 | 2019-06-19 | 4 | Hughes Thomas E. | MGEN | Stock Option (right to buy) | D | 2,36 | 12.000 | 12.000 | |||||
| 2019-06-21 | 2019-06-19 | 4 | KOCH KEVIN | MGEN | Stock Option (right to buy) | D | 2,36 | 12.000 | 12.000 | |||||
| 2019-06-21 | 2019-06-19 | 4 | Morris Arlene | MGEN | Stock Option (right to buy) | D | 2,36 | 12.000 | 12.000 | |||||
| 2019-06-21 | 2019-06-19 | 4 | TURNER JOSEPH L | MGEN | Stock Option (right to buy) | D | 2,36 | 12.000 | 12.000 | |||||
| 2019-04-05 | 2019-04-03 | 4 | Hughes Thomas E. | MGEN | Stock Option (right to buy) | D | 2,99 | 10.106 | 10.106 | |||||
| 2019-02-08 | 2019-02-06 | 4 | Marshall William Stuart | MGEN | Stock Option (right to buy) | D | 2,96 | 232.000 | 232.000 | |||||
| 2019-02-08 | 2019-02-06 | 4 | Leverone Jason A. | MGEN | Stock Option (right to buy) | D | 2,96 | 75.000 | 75.000 | |||||
| 2019-02-08 | 2019-02-06 | 4 | Levy Adam Scott | MGEN | Stock Option (right to buy) | D | 2,96 | 74.000 | 74.000 | |||||
| 2019-02-08 | 2019-02-06 | 4 | RUBIN PAUL D | MGEN | Stock Option (right to buy) | D | 2,96 | 87.000 | 87.000 | |||||
| 2018-10-12 | 2018-10-11 | 4 | Hughes Thomas E. | MGEN | Common Stock | D | 4,7697 | 10.000 | 48 | 12.827 | ||||
| 2018-08-09 | 2018-08-07 | 4 | Leverone Jason A. | MGEN | Stock Option (right to buy) | D | 0,57 | -29.530 | 0 | |||||
| 2018-08-09 | 2018-08-07 | 4 | Leverone Jason A. | MGEN | Common Stock | D | 0,5700 | 29.530 | 17 | 30.737 | ||||
| 2018-06-28 | 2018-06-27 | 4 | Morris Arlene | MGEN | Stock Option (right to buy) | D | 6,46 | 12.000 | 12.000 | |||||
| 2018-06-28 | 2018-06-27 | 4 | TURNER JOSEPH L | MGEN | Stock Option (right to buy) | D | 6,46 | 12.000 | 12.000 | |||||
| 2018-06-28 | 2018-06-27 | 4 | Booth Bruce | MGEN | Stock Option (right to buy) | D | 6,46 | 12.000 | 12.000 | |||||
| 2018-06-28 | 2018-06-27 | 4 | Bowden Christopher | MGEN | Stock Option (right to buy) | D | 6,46 | 12.000 | 12.000 | |||||
| 2018-06-28 | 2018-06-27 | 4 | Hatfield Jeffrey S. | MGEN | Stock Option (right to buy) | D | 6,46 | 12.000 | 12.000 | |||||
| 2018-06-28 | 2018-06-27 | 4 | Hughes Thomas E. | MGEN | Stock Option (right to buy) | D | 6,46 | 12.000 | 12.000 | |||||
| 2018-06-28 | 2018-06-27 | 4 | KOCH KEVIN | MGEN | Stock Option (right to buy) | D | 6,46 | 12.000 | 12.000 | |||||
| 2018-02-15 | 2018-02-13 | 4 | Marshall William Stuart | MGEN | Stock Option (right to buy) | D | 0,57 | -115.818 | 0 | |||||
| 2018-02-15 | 2018-02-13 | 4 | Marshall William Stuart | MGEN | Common Stock | D | 0,5700 | 115.818 | 66 | 265.646 | ||||
| 2018-02-13 | 2018-02-13 | 4 | Booth Bruce | MGEN | Common Stock | I | 5,5000 | 545.454 | 3.000 | 1.351.090 | ||||
| 2018-02-13 | 2018-02-13 | 4 | Levy Adam Scott | MGEN | Common Stock | D | 5,5000 | 9.090 | 50 | 10.540 | ||||
| 2018-02-02 | 2018-01-31 | 4 | Marshall William Stuart | MGEN | Stock Option (right to buy) | D | 7,50 | 245.000 | 245.000 | |||||
| 2018-02-02 | 2018-01-31 | 4 | RUBIN PAUL D | MGEN | Stock Option (right to buy) | D | 7,50 | 85.000 | 85.000 | |||||
| 2018-02-02 | 2018-01-31 | 4 | Levy Adam Scott | MGEN | Stock Option (right to buy) | D | 7,50 | 80.000 | 80.000 | |||||
| 2018-02-02 | 2018-01-31 | 4 | Leverone Jason A. | MGEN | Stock Option (right to buy) | D | 7,50 | 75.000 | 75.000 | |||||
| 2018-01-05 | 2018-01-03 | 4 | Booth Bruce | MGEN | Stock Option (right to buy) | D | 9,72 | 10.191 | 10.191 | |||||
| 2018-01-05 | 2018-01-03 | 4 | Hughes Thomas E. | MGEN | Stock Option (right to buy) | D | 9,72 | 3.426 | 3.426 | |||||
| 2017-12-22 | 2017-12-20 | 4 | Hughes Thomas E. | MGEN | Common Stock | D | 8,0000 | -12.000 | -96 | 2.827 | ||||
| 2017-06-30 | 2017-06-28 | 4 | KOCH KEVIN | MGEN | Stock Option (right to buy) | D | 12,06 | 12.000 | 12.000 | |||||
| 2017-06-30 | 2017-06-28 | 4 | LEFKOFF KYLE | MGEN | Stock Option (right to buy) | D | 12,06 | 12.000 | 12.000 | |||||
| 2017-06-30 | 2017-06-28 | 4 | Booth Bruce | MGEN | Stock Option (right to buy) | D | 12,06 | 12.000 | 12.000 | |||||
| 2017-06-30 | 2017-06-28 | 4 | Hughes Thomas E. | MGEN | Stock Option (right to buy) | D | 12,06 | 12.000 | 12.000 | |||||
| 2017-06-30 | 2017-06-28 | 4 | Creecy John W | MGEN | Stock Option (right to buy) | D | 12,06 | 12.000 | 12.000 | |||||
| 2017-06-30 | 2017-06-28 | 4 | TURNER JOSEPH L | MGEN | Stock Option (right to buy) | D | 12,06 | 12.000 | 12.000 | |||||
| 2017-06-23 | 2017-06-22 | 4 | Levy Adam Scott | MGEN | Common Stock | D | 7,5500 | 200 | 2 | 200 | ||||
| 2017-03-28 | 2017-03-24 | 4 | Booth Bruce | MGEN | Stock Option (right to buy) | D | 11,80 | 6.844 | 6.844 | |||||
| 2017-03-28 | 2017-03-24 | 4 | Hughes Thomas E. | MGEN | Stock Option (right to buy) | D | 11,80 | 1.191 | 1.191 | |||||
| 2017-03-28 | 2017-03-24 | 4 | Hughes Thomas E. | MGEN | Common Stock | D | 778 | 14.840 | ||||||
| 2017-03-13 | 2017-03-10 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 14,3118 | -3.300 | -47 | 463.473 | ||||
| 2017-03-13 | 2017-03-09 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 14,3846 | -2.500 | -36 | 466.773 | ||||
| 2017-03-08 | 2017-03-08 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 14,7028 | -5.000 | -74 | 469.273 | ||||
| 2017-03-08 | 2017-03-06 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 16,2398 | -608 | -10 | 474.273 | ||||
| 2017-03-08 | 2017-03-06 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 15,7144 | -9.392 | -148 | 474.881 | ||||
| 2017-02-28 | 2017-02-28 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 13,5430 | -2.258 | -31 | 484.273 | ||||
| 2017-02-28 | 2017-02-27 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 13,7910 | -1.500 | -21 | 486.531 | ||||
| 2017-02-28 | 2017-02-24 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 14,0388 | -6.500 | -91 | 488.031 | ||||
| 2017-02-24 | 2017-02-23 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 13,6477 | -1.800 | -25 | 494.531 | ||||
| 2017-02-24 | 2017-02-22 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 14,3554 | -4.102 | -59 | 496.331 | ||||
| 2017-02-16 | 2017-02-16 | 4 | RUBIN PAUL D | MGEN | Stock Option (right to buy) | D | 11,01 | 87.500 | 87.500 | |||||
| 2017-02-16 | 2017-02-16 | 4 | Leverone Jason A. | MGEN | Stock Option (right to buy) | D | 11,01 | 77.500 | 77.500 | |||||
| 2017-02-16 | 2017-02-16 | 4 | Marshall William Stuart | MGEN | Stock Option (right to buy) | D | 11,01 | 200.000 | 200.000 | |||||
| 2017-02-16 | 2017-02-16 | 4 | Levy Adam Scott | MGEN | Stock Option (right to buy) | D | 11,01 | 87.500 | 87.500 | |||||
| 2017-02-13 | 3 | Creecy John W | MGEN | Common Stock | I | 5.413.126 | ||||||||
| 2017-02-13 | 3 | Creecy John W | MGEN | Common Stock | I | 5.413.126 | ||||||||
| 2017-02-13 | 3 | Remeditex Ventures LLC | MGEN | Common Stock | D | 5.413.126 | ||||||||
| 2017-02-13 | 3 | Remeditex Ventures LLC | MGEN | Common Stock | D | 5.413.126 | ||||||||
| 2017-02-13 | 3 | Atlas Venture Fund VII L P | MGEN | Common Stock | D | 6.285.160 | ||||||||
| 2017-02-13 | 3 | Atlas Venture Fund VII L P | MGEN | Common Stock | D | 6.285.160 | ||||||||
| 2017-02-13 | 3 | LEFKOFF KYLE See Footnotes | MGEN | Common Stock | I | 2.608.303 | ||||||||
| 2017-02-13 | 3 | LEFKOFF KYLE See Footnotes | MGEN | Common Stock | I | 2.608.303 | ||||||||
| 2017-02-13 | 3 | LEFKOFF KYLE See Footnotes | MGEN | Common Stock | I | 3.715.307 | ||||||||
| 2017-02-13 | 3 | LEFKOFF KYLE See Footnotes | MGEN | Common Stock | I | 3.715.307 | ||||||||
| 2017-02-13 | 3 | Marshall William Stuart | MGEN | Common Stock | D | 297.156 | ||||||||
| 2017-02-13 | 3 | Marshall William Stuart | MGEN | Common Stock | D | 297.156 | ||||||||
| 2017-02-13 | 3 | Booth Bruce | MGEN | Common Stock | I | 7.090.796 | ||||||||
| 2017-02-13 | 3 | Booth Bruce | MGEN | Common Stock | I | 7.090.796 | ||||||||
| 2017-02-13 | 3 | Booth Bruce | MGEN | Common Stock | I | 4.753.852 | ||||||||
| 2017-02-13 | 3 | Booth Bruce | MGEN | Common Stock | I | 4.753.852 | ||||||||
| 2017-02-13 | 3 | Hughes Thomas E. | MGEN | Common Stock | D | 28.124 | ||||||||
| 2017-02-13 | 3 | Hughes Thomas E. | MGEN | Common Stock | D | 28.124 | ||||||||
| 2017-02-13 | 2017-02-13 | 4 | LEBOW BENNETT S | MGEN | Unsecured Demand Promissory Note | D | 5,39 | 0 | ||||||
| 2017-02-13 | 2017-02-13 | 4 | LEBOW BENNETT S | MGEN | Unsecured Demand Promissory Note | D | 5,39 | |||||||
| 2017-02-13 | 2017-02-13 | 4 | LEBOW BENNETT S | MGEN | Common Stock | D | 5,3900 | 279.067 | 1.504 | 280.600 | ||||
| 2017-02-08 | 2017-02-08 | 4 | Gonyer David A | SGNL | Stock Option (Right to Buy) | D | 7,65 | -1.200 | 0 | |||||
| 2017-02-08 | 2017-02-08 | 4 | Gonyer David A | SGNL | Common Stock | D | 7,6500 | 1.200 | 9 | 1.899 | ||||
| 2017-02-07 | 2017-02-03 | 4 | Smith Robin L | SGNL | Stock Option (Right to Buy) | D | 7,65 | -1.200 | 0 | |||||
| 2017-02-07 | 2017-02-03 | 4 | Smith Robin L | SGNL | Common Stock | D | 7,6500 | 1.200 | 9 | 1.900 | ||||
| 2017-02-07 | 2017-02-03 | 4 | LEBOW BENNETT S | SGNL | Stock Option (Right to Buy) | D | 7,65 | -1.200 | 0 | |||||
| 2017-02-07 | 2017-02-03 | 4 | LEBOW BENNETT S | SGNL | Common Stock | D | 7,6500 | 1.200 | 9 | 1.533 | ||||
| 2016-11-02 | 2016-10-31 | 4 | Riccitelli Samuel D | SGNL | Restricted Stock Units | D | 0,00 | -200.000 | 0 | |||||
| 2016-11-02 | 2016-10-31 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 0,3600 | -103.160 | -37 | 571.370 | ||||
| 2016-11-02 | 2016-10-31 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 200.000 | 674.530 | ||||||
| 2016-11-02 | 2016-10-31 | 4 | SEYMOUR TAMARA A | SGNL | Restricted Stock Units | D | -100.000 | 0 | ||||||
| 2016-11-02 | 2016-10-31 | 4 | SEYMOUR TAMARA A | SGNL | Restricted Stock Units | D | -46.000 | 0 | ||||||
| 2016-11-02 | 2016-10-31 | 4 | SEYMOUR TAMARA A By Trust | SGNL | Common Stock | I | 0,3600 | -45.580 | -16 | 106.447 | ||||
| 2016-11-02 | 2016-10-31 | 4 | SEYMOUR TAMARA A By Trust | SGNL | Common Stock | I | 100.000 | 152.027 | ||||||
| 2016-11-02 | 2016-10-31 | 4 | SEYMOUR TAMARA A By Trust | SGNL | Common Stock | I | 0,3600 | -20.967 | -8 | 52.027 | ||||
| 2016-11-02 | 2016-10-31 | 4 | SEYMOUR TAMARA A By Trust | SGNL | Common Stock | I | 46.000 | 72.994 | ||||||
| 2016-08-10 | 2016-08-08 | 4 | SEYMOUR TAMARA A | SGNL | Restricted Stock Units | D | -23.000 | 46.000 | ||||||
| 2016-08-10 | 2016-08-08 | 4 | SEYMOUR TAMARA A By Trust | SGNL | Common Stock | I | 0,4850 | -10.484 | -5 | 26.994 | ||||
| 2016-08-10 | 2016-08-08 | 4 | SEYMOUR TAMARA A By Trust | SGNL | Common Stock | I | 23.000 | 37.478 | ||||||
| 2016-06-30 | 2016-06-28 | 4 | Riccitelli Samuel D | SGNL | Restricted Stock Units | D | 0,00 | -124.251 | 0 | |||||
| 2016-06-30 | 2016-06-28 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 0,4600 | -64.835 | -30 | 474.530 | ||||
| 2016-06-30 | 2016-06-28 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 124.251 | 539.365 | ||||||
| 2016-06-20 | 2016-06-15 | 4 | Gonyer David A | SGNL | Stock Option (Right to Buy) | D | 0,51 | 18.000 | 18.000 | |||||
| 2016-06-20 | 2016-06-15 | 4 | Schuling Douglas A | SGNL | Stock Option (Right to Buy) | D | 0,51 | 18.000 | 18.000 | |||||
| 2016-06-20 | 2016-06-15 | 4 | Smith Robin L | SGNL | Stock Option (Right to Buy) | D | 0,51 | 18.000 | 18.000 | |||||
| 2016-06-20 | 2016-06-15 | 4 | LEBOW BENNETT S | SGNL | Stock Option (Right to Buy) | D | 0,51 | 18.000 | 18.000 | |||||
| 2016-05-19 | 2016-03-28 | 4 | Riccitelli Samuel D | SGNL | Restricted Stock Units | D | 0,00 | 200.000 | 200.000 | |||||
| 2016-05-19 | 2016-03-28 | 4 | SEYMOUR TAMARA A | SGNL | Restricted Stock Units | D | 0,00 | 100.000 | 100.000 | |||||
| 2016-02-12 | 2016-02-11 | 4 | Riccitelli Samuel D | SGNL | Restricted Stock Units | D | 0,00 | -124.252 | 124.251 | |||||
| 2016-02-12 | 2016-02-11 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 0,4600 | -54.268 | -25 | 415.114 | ||||
| 2016-02-12 | 2016-02-11 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 124.252 | 469.382 | ||||||
| 2015-11-23 | 2015-11-20 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 0,8000 | 7.000 | 6 | 345.130 | ||||
| 2015-11-23 | 2015-11-19 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 0,7800 | 7.000 | 5 | 338.130 | ||||
| 2015-08-14 | 2015-08-12 | 4 | SEYMOUR TAMARA A | SGNL | Employee Stock Option (Right to Buy) | D | 1,57 | 60.000 | 60.000 | |||||
| 2015-08-10 | 2015-08-06 | 4 | Gonyer David A | SGNL | Stock Option (Right to Buy) | D | 1,62 | 18.000 | 18.000 | |||||
| 2015-08-10 | 2015-08-06 | 4 | Gonyer David A | SGNL | Restricted Stock Units | D | -4.125 | 0 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | Gonyer David A | SGNL | Common Stock | D | 5.000 | 10.500 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | Gonyer David A | SGNL | Common Stock | D | 4.125 | 5.500 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | Schuling Douglas A | SGNL | Stock Option (Right to Buy) | D | 1,62 | 18.000 | 18.000 | |||||
| 2015-08-10 | 2015-08-06 | 4 | Schuling Douglas A | SGNL | Restricted Stock Units | D | -4.125 | 0 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | Schuling Douglas A | SGNL | Common Stock | D | 5.000 | 10.500 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | Schuling Douglas A | SGNL | Common Stock | D | 4.125 | 5.500 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | Smith Robin L | SGNL | Stock Option (Right to Buy) | D | 1,62 | 18.000 | 18.000 | |||||
| 2015-08-10 | 2015-08-06 | 4 | Smith Robin L | SGNL | Restricted Stock Units | D | -4.125 | 0 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | Smith Robin L | SGNL | Common Stock | D | 5.000 | 10.500 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | Smith Robin L | SGNL | Common Stock | D | 4.125 | 5.500 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | LEBOW BENNETT S | SGNL | Stock Option (Right to Buy) | D | 1,62 | 18.000 | 18.000 | |||||
| 2015-08-10 | 2015-08-06 | 4 | LEBOW BENNETT S | SGNL | Common Stock | D | 5.000 | 5.000 | ||||||
| 2015-08-05 | 2015-08-04 | 4 | SEYMOUR TAMARA A | SGNL | Restricted Stock Units | D | -23.000 | 69.000 | ||||||
| 2015-08-05 | 2015-08-04 | 4 | SEYMOUR TAMARA A | SGNL | Common Stock | D | 1,5600 | -8.522 | -13 | 14.478 | ||||
| 2015-08-05 | 2015-08-04 | 4 | SEYMOUR TAMARA A | SGNL | Common Stock | D | 23.000 | 23.000 | ||||||
| 2015-07-21 | 2015-07-17 | 4 | Smith Robin L | SGNL | Restricted Stock Units | D | -1.375 | 4.125 | ||||||
| 2015-07-21 | 2015-07-17 | 4 | Smith Robin L | SGNL | Common Stock | D | 1.375 | 1.375 | ||||||
| 2015-07-21 | 2015-07-17 | 4 | Schuling Douglas A | SGNL | Restricted Stock Units | D | -1.375 | 4.125 | ||||||
| 2015-07-21 | 2015-07-17 | 4 | Schuling Douglas A | SGNL | Common Stock | D | 1.375 | 1.375 | ||||||
| 2015-07-21 | 2015-07-17 | 4 | Gonyer David A | SGNL | Restricted Stock Units | D | -1.375 | 4.125 | ||||||
| 2015-07-21 | 2015-07-17 | 4 | Gonyer David A | SGNL | Common Stock | D | 1.375 | 1.375 | ||||||
| 2015-06-23 | 2015-06-19 | 4 | Riccitelli Samuel D | SGNL | Restricted Stock Units | D | -124.252 | 248.503 | ||||||
| 2015-06-23 | 2015-06-19 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 1,5100 | -46.036 | -70 | 331.130 | ||||
| 2015-06-23 | 2015-06-19 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 124.252 | 377.166 | ||||||
| 2015-04-10 | 2015-04-08 | 4 | Riccitelli Samuel D | SGNL | Restricted Stock Units | D | -372.756 | 372.755 | ||||||
| 2015-04-10 | 2015-04-08 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 2,0800 | -119.842 | -249 | 252.914 | ||||
| 2015-04-10 | 2015-04-08 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 372.756 | 372.756 | ||||||
| 2014-08-04 | 2014-08-04 | 4 | SEYMOUR TAMARA A | SGNL | Restricted Stock Units | D | 92.000 | 92.000 | ||||||
| 2014-07-21 | 2014-07-17 | 4 | Smith Robin L | SGNL | Restricted Stock Units | D | 5.500 | 5.500 | ||||||
| 2014-07-21 | 2014-07-17 | 4 | Smith Robin L | SGNL | Stock Option (right to buy) | D | 5,60 | 6.000 | 6.000 | |||||
| 2014-07-21 | 2014-07-17 | 4 | Gonyer David A | SGNL | Restricted Stock Units | D | 5.500 | 5.500 | ||||||
| 2014-07-21 | 2014-07-17 | 4 | Gonyer David A | SGNL | Stock Option (right to buy) | D | 5,60 | 6.000 | 6.000 | |||||
| 2014-07-21 | 2014-07-17 | 4 | Schuling Douglas A | SGNL | Restricted Stock Units | D | 5.500 | 5.500 | ||||||
| 2014-07-21 | 2014-07-17 | 4 | Schuling Douglas A | SGNL | Stock Option (right to buy) | D | 5,60 | 6.000 | 6.000 | |||||
| 2014-06-17 | 3 | LEBOW ALPHA, LLLP By LeBow Alpha, LLLP | SGNL | Common Stock, par value $0.01 per share | I | 4.465.258 | ||||||||
| 2014-06-17 | 3 | LEBOW ALPHA, LLLP By LeBow Alpha, LLLP | SGNL | Common Stock, par value $0.01 per share | I | 4.465.258 | ||||||||
| 2014-06-17 | 3 | LEBOW ALPHA, LLLP By LeBow Alpha, LLLP | SGNL | Common Stock, par value $0.01 per share | I | 4.465.258 |
P
Piața deschisă sau achiziția privată de titluri nederivate sau derivate
S
Piața deschisă sau vânzarea privată a titlurilor de valoare nederivate sau derivate
A
Acordarea, atribuirea sau alte achiziții de valori mobiliare de la companie (cum ar fi o opțiune)
C
Conversia derivatei
D
Vânzarea sau transferul de valori mobiliare înapoi către companie
F
Plata prețului de exercițiu sau a obligației fiscale folosind o parte din titlurile de valoare primite de la companie
G
Donarea de valori mobiliare de către sau către persoane din interior
K
Swap-uri de acțiuni și tranzacții similare de acoperire împotriva riscurilor
M
Exercitarea sau conversia titlurilor derivate primite de la companie (cum ar fi o opțiune)
V
O tranzacție raportată voluntar pe Formularul 4
J
Altele (însoțite de o notă de subsol care descrie tranzacția)
